User profiles for S. Dubé

Sourabh Dube

Associate Professor of Physics, IISER Pune
Verified email at iiserpune.ac.in
Cited by 237545

[PDF][PDF] Étude exploratoire des besoins en services offerts à la clientèle traumatisée cranio-cérébrale au Québec

M Gervais, S Dubé - Québec, Canada: Institut de Réadaptation en …, 1999 - inesss.qc.ca
… dans ce contexte d’actualisation à court terme d’un continuum de services favorisant une
réponse optimale aux besoins des personnes ayant subi un traumatisme cranio-cérébral que s’…

Polarizations of and Mesons Produced in Collisions at

…, C Dörr, S Donati, P Dong, J Donini, T Dorigo, S Dube… - Physical review …, 2007 - APS
We have measured the polarizations of J/ψ and ψ (2 S) mesons as functions of their transverse
momentum p T when they are produced promptly in the rapidity range| y|< 0.6 with p T≥ …

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

…, RW Baker, AR Evans, K Beymer, S Dubé… - Archives of general …, 2003 - jamanetwork.com
… Thus, all reported MADRS, MADRS item, CGI-BP-S, and YMRS mean change scores
represent least squares means. The MMRM analyses were performed using the SAS PROC …

[PDF][PDF] Les représentations du système scolaire des familles issues de milieux défavorisés

…, A Anne, S Dubé, S Goulet - Groupe de recherche sur l' …, 2009 - researchgate.net
… 1 Pour un bilan complet des quarante dernières années d’intervention, vous pouvez consulter
le texte suivant dont s’inspire l’introduction de cet article : Deniger, MA et Roy, G. (2008). L…

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.

…, TM Sanger, SB Watson, S Dubé - Journal of Clinical …, 2007 - psychiatrist.com
… Whether or not the patient achieved a satisfactory response during this historical antidepressant
trial was left to the investigator’s clinical judgment. Consenting patients meeting these cri…

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

…, J Lienemann D Pharm, S Dubé… - American Journal of …, 2008 - Am Psychiatric Assoc
… The efficacy of xanomeline in Alzheimer’s-type dementia was … by the Alzheimer’s Disease
Assessment Scale cognitive … of the study of xanomeline in Alzheimer’s dementia (21) , the …

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data

CH Mallinckrodt, TM Sanger, S Dubé, DJ DeBrota… - Biological …, 2003 - Elsevier
… For example, consider Alzheimer’s disease, for which the … A’s dropout was small because
the last observation was close to the trial’s end point, whereas the impact from patient B’s

What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

…, R Anand, G Awad, M Davidson, S Dubé… - Schizophrenia …, 2010 - academic.oup.com
On September 18, 2007, a collaborative session between the International Society for CNS
Clinical Trials and Methodology and the International Society for CNS Drug Development …

Research issues in the study of difficult-to-treat depression

AJ Rush, ME Thase, S Dubé - Biological psychiatry, 2003 - Elsevier
… Thus both a cap on the number of failed trials in the patient’s lifetime and the number of
failed trials in the current episode would be needed to exclude highly resistant forms of TRD. …

The hydrolysis of imidate salts. Stereoelectronic control in the cleavage of the hemiorthoamide tetrahedral intermediate

P Deslongchamps, S Dubé, C Lebreux… - Canadian Journal of …, 1975 - cdnsciencepub.com
Une nouvelle théorie stéréoélectronique sur la décomposition de l'intermédiaire tétrahédrique
(hémi-orthoamide) au cours de l'hydrolyse des amides est présentée. Dans cette nouvelle …